Case number 1:23-cv-01268
AbbVie Inc. v. Teva Pharmaceuticals, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jan 3, 2024 | 10 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,690,845 B2. (Attachments: # 1 Order)(nms) (Entered: 01/03/2024) (0) |
| Jan 2, 2024 | N/A | DEFICIENCY NOTICE issued by the Court to Defendants: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (nms) (Entered: 01/02/2024) (0) |
| Jan 2, 2024 | 8 | SO ORDERED Granting 6 Stipulation and Proposed Order of Dismissal (*Teva Pharmaceutical Industries Ltd. terminated). Signed by Judge Richard G. Andrews on 1/2/2024. (nms) (Main Document 8 replaced on 1/2/2024) (nms). (Entered: 01/02/2024) (3) |
| Jan 2, 2024 | 9 | SO ORDERED Granting 7 Stipulation and Proposed Order of Dismissal (***Civil Case Terminated). Signed by Judge Richard G. Andrews on 1/2/2024. (nms) (Entered: 01/02/2024) (4) |
| Jan 2, 2024 | N/A | CORRECTING ENTRY: The pdf for D.I. 8 has been replaced with a corrected version. The NEF for the filing has been regenerated. (nms) (Entered: 01/02/2024) (0) |
| Dec 22, 2023 | 6 | STIPULATION of Dismissal as to Teva Pharmaceutical Industries Ltd., by AbbVie Inc.. (Tigan, Jeremy) Modified on 12/26/2023 (nms). (Entered: 12/22/2023) (3) |
| Dec 22, 2023 | 7 | STIPULATION of Dismissal by AbbVie Inc.. (Tigan, Jeremy) (Entered: 12/22/2023) (4) |
| Nov 15, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 11/15/2023) (0) |
| Nov 7, 2023 | 1 | Complaint* (1) |
| Nov 7, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 11/07/2023) (3) |
| Nov 7, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/20/2023. Date of Expiration of Patent: 8/27/2040.Thirty Month Stay Deadline: 1/23/2026. (mpb) (Entered: 11/07/2023) (1) |
| Nov 7, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,690,845 B2. (mpb) (Entered: 11/07/2023) (1) |
| Nov 7, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc.. (mpb) (Entered: 11/07/2023) (1) |
| Nov 7, 2023 | N/A | No Summons Issued. (mpb) (Entered: 11/07/2023) (0) |
